This NETCast episode features Dr. Uday Grewal hosting a discussion with Drs. Aman Chauhan, Renuka Iyer, and Shagufta Shaheen on the complexities of hybrid neuroendocrine cancers. The panel explores transformation cases, mixed histology, and emerging DLL3-targeted therapies with lung cancer and CAR-T expertise. See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

This NETCast episode from the 2025 NANETS Symposium features Dr. Theodora Dimitra hosting a discussion with Drs. Alexandria Phan, Paul Herr, Dawn Quelle, and Andrew Bellizzi on a range of hot topics. The panel discusses challenging NET clinical scenarios including biomarkers, GLP-1 medications, and surgical decision-making. See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

This episode of NETCast features Dr. Thorvardur Halfdanarson (Mayo Clinic oncologist) and Burt Rosen (patient advocate) discussing artificial intelligence's role in transforming healthcare, particularly for NET patients. Both guests agree AI represents a truly transformative shift—not just another overhyped technology—with potential to revolutionize drug discovery, clinical trial design, and most importantly, move medicine from population-based treatment to individualized care. They also discuss key ethical considerations such as data ownership, patient consent for AI use in care, and ensuring models are trained on diverse populations to avoid amplifying existing biases. See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

This episode of NETcast features a "presidential panel" of three distinguished NANETS leaders: Dr. Jennifer Chan (president 2025, Dana-Farber), Dr. Simran Singh (incoming president, Sunnybrook), and Dr. Thorvardur Halfdanarson (president emeritus, Mayo Clinic). The discussion covers transformative developments in NET management over the past decade, including radiopharmaceuticals, targeted therapies, and the recognition that NETs may be less rare than previously thought. The experts explore the future of alpha and beta particle therapy retreatment protocols, challenges in biomarker development, and the importance of treatment sequencing given disease heterogeneity. The panel also discusses the importance of mentorship and the welcoming nature of the NET community in nurturing early-career researchers, while acknowledging that future progress will likely come through incremental advances and optimal treatment sequencing rather than single breakthrough therapies. See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

This episode of NETCast features a panel on NET patient advocacy. They explore why advocacy is critical for this rare cancer, discussing challenges patients face at diagnosis, the importance of education and resources, research funding obstacles, and political advocacy efforts. The panel emphasizes that patients should be active participants in advocacy—whether through contacting reprsentatives, supporting research organizations, or engaging in educational initiatives—to make this "invisible" disease visible and drive meaningful change in treatment and outcomes. See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

This podcast episode discusses the current state of neuroendocrine tumors in Latin America, focusing on the challenges and advancements in diagnosis and treatment. Experts from various countries share insights on the importance of education, registration, and multidisciplinary approaches in managing these tumors. The role of international societies like NANETS in supporting research and education is emphasized, along with the need for increased participation in clinical trials and improved access to treatment options for patients. See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

In this conversation, Jason Starr and Jessica Thomas discuss the critical intersection of mental health and oncology. They explore personal experiences with mental health challenges, the prevalence of burnout among healthcare providers, and the importance of resilience and wellness strategies. The discussion also delves into compassion fatigue, the necessity of setting boundaries for self-care, and the value of community support in navigating these challenges. The conversation emphasizes that mental health is a journey and encourages open dialogue about struggles in the healthcare field. See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

In this podcast, Dr. Garima Gupta meets with Dr. Renuka Iyer and Dr. Aman Chauhan to discuss the latest advancements in the treatment of neuroendocrine carcinomas, focusing on the differences between pulmonary and extra pulmonary types, treatment strategies for extensive stage cases, and the challenges faced in treating platinum refractory patients. They highlight the importance of clinical trials and innovative therapies, including DLL3 targeting and oncolytic virus studies, while emphasizing the need for ongoing research and patient participation in trials. See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

In this episode of the NET Podcast, Dr. Arshad meets with Dr. Soares, Dr. Shaheen, and Dr. Sonbol at the Tucson Regional Conference to discuss the evolving landscape of neuroendocrine tumors, focusing on recent studies such as the COMPETE study and the implications for treatment sequencing and patient care. They explore the importance of individualized treatment plans, the role of new therapies like cabozantinib, and the real-world challenges faced by patients, including financial toxicity. The conversation highlights the need for ongoing research and collaboration in the field. See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

¡Bienvenidos a nuestro primer podcast en español! En este episodio, el Dr. Ismael Domínguez Rosado hablará con la Dra. Cecilia Carreras y la Dra. Mónica Isabel Meneses Medina para revisar la agenda de nuestra Conferencia Regional en la Ciudad de México. Luego, discutirán terapias locales y regionales para tumores endocrinos en México. See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

In this episode of NETCAST, neuroendocrine experts Dr. Mosalem and Dr. Wahl meet with Taymeyah Al-Toubah discuss the latest advancements in neuroendocrine tumor treatments, focusing on peptide receptor radionuclide therapy (PRRT) with alpha and beta emitters. They delve into the safety and efficacy of new investigational agents, the challenges of hematological toxicity, and the importance of multidisciplinary teams in managing patient care. The conversation highlights the evolving landscape of neuroendocrine tumor therapies and the need for ongoing research and collaboration. See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

In this podcast episode, neuroendocrine experts Dr. Liu and Dr. Gujarathi meet with Dr. Phan to discuss the latest advancements in neuroendocrine tumor research, focusing on innovative models for studying G1 and G2 neuroendocrine tumors, the implications of genetic mutations in pancreatic neuroendocrine tumors, and the future of drug screening and treatment protocols. The conversation highlights the importance of developing effective therapies tailored to individual patient profiles and the potential for new biomarkers to guide treatment decisions. See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

In this episode of NETCAST, leading neuroendocrine experts Dr. Mohammed and Dr. Chauhan meet with Dr. Gangi to discuss their recent studies on innovative therapies for neuroendocrine tumors. Dr. Chauhan presents findings on Peltocetine, a new oral somatostatin receptor agonist, highlighting its efficacy in treating carcinoid syndrome. Dr. Mohammed shares insights on NP101, a combination therapy for metastatic neuroendocrine carcinomas, emphasizing its potential in enhancing treatment outcomes. The conversation explores the future of neuroendocrine cancer treatment, focusing on patient preferences and the importance of ongoing research. See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

In this episode of NETCast, Dr. Jason Starr engages with patient advocacy leaders in the NET community to review highlights and insights from the 2024 NANETS Annual Symposium. Lisa Yen, Jessica Thomas, and Josh Mailman discuss the evolving role of patients in their care, the need for more therapies for neuroendocrine carcinoma, and the significance of building trust between patients and healthcare providers. The panelists share their experiences and strategies for empowering patients and bridging gaps in clinical trials and education. See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

In this episode, Dr. Aman Chauhan joins Dr. Renuka Iyer to discuss the critical updates in neuroendocrine tumors, focusing on the AJCC staging system and its implications for clinical practice. The conversation covers the evolution of staging systems, the role of biomarkers like chromogranin A, the importance of endoscopists in management, and the outcomes for appendiceal neuroendocrine tumors. The episode emphasizes the need for updated guidelines to improve patient care and outcomes in the field of oncology. See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

DLL3 approval in eSCLC and how it can be used in extrapulmonary PDNEC/small cell. Dr. Phan speaks with Dr. Jain about treatment options for neuroendocrine carcinoma. See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

NET Regional Education Conference Jointly Provided by The University of Minnesota and The Mayo Clinic. Dr. Lou and Dr. Halfdanarson spoke with Dr. Phan and Dr. Chandrasekharan about Systemic Therapy for NETs Beyond SSAs (Including Sequencing) and Well-differentiated G3 NETs. See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Join us for Episode 24 of NETCast. Mayo Clinical Gastrointestinal Oncologist Dr. Jason Starr interviews Lisa Yen from LACNETS and Stephanie Alband from INCA and The PheoPara Alliance, patient advocacy groups that partner with NANETS. Join us as we discuss ways we are Bridging the Gap for patient advocacy. See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Join us for Episode 23 of NETCast. Ohio State University Medical Oncology Specialist Dr. Vineeth Sukrithan interviews Dr. Simron Singh professor of medicine at the University of Toronto and co-founder of the Susan Leslie Clinic for Neuroendocrine Tumors. He is also a medical oncologist and affiliate scientist in the Odette Cancer Research Program at Sunnybrook Research Institute. Join us as we review the NETTER-1 study and then discuss the NETTER-2 study. See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Join us for Episode 22 of NETCast. Mayo Clinical Gastrointestinal Oncologist Dr. Jason Starr interviews Hematologist & Oncologist Dr. Bassam Sonbol about bone marrow toxicity associated with PRRT. See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.